- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04894734
Spinal Cord Stimulation (SCS) for Spinal Cord Injury (SCI)
The Feasibility of Epidural Electrical Stimulation (EES) for Improving Pain and Rehabilitation Outcomes in Patients With Spinal Cord Injury (SCI)
The purpose of this feasibility study is to compare the impact of Spinal cord stimulation [SCS] for Spinal Cord Injury (SCI) pain and rehabilitation. SCS, also known as Epidural Electrical Stimulation (EES), will be utilized along with conventional medical management (CMM) or CMM alone. Participation in this research study is expected to last approximately 12 months. All subjects will be evaluated and proceed with implantation of two SCS devices- one tailored based on the individual's SCI for the treatment of neuropathic pain of trunk and limb and a second near the bottom of the spinal cord (conus region) to study the impact on motor, sensory, bowel/bladder outcomes. All patients will also continue receiving CMM, such as medications and physical therapy.
Participating subjects will be randomly assigned to one of two treatment groups:
- Placebo arm: SCS OFF + CMM. Under the direction of the study physician, the patient may receive a variety of treatments, such as medications and various forms of rehabilitation.
- Treatment arm: SCS ON + CMM. The study treatment Spinal Cord Stimulation [SCS]: the study physician will perform a trial procedure to see if the study procedure works for the patient and may implant a permanent device if it is successful. There is a temporary trial procedure, or a "test drive," which usually lasts 5-7 days. If this is successful, patients will discuss a more permanent implant. This study involves the concurrent placement of two SCS devices (one focused on pain and the second for rehabilitation).
For three months, treatment group subjects will have the SCS turned on and will have rehabilitation as part of their CMM. Participants in the placebo arm will have their SCS remain off and will undergo CMM with rehabilitation therapy similar to the treatment group. Neither the subjects nor the treatment team will know which patients are in the treatment or placebo arm.
At the end of three months, the study group will be revealed and the placebo group subjects will be allowed to crossover and have their SCS turned on. Rehabilitation visits may be remote and the study duration is approximately 12 months. There may be additional blood tests and clinical exams to collect data on the effectiveness of the therapy. Data at follow-up visits will be compared to the subjects' baseline data and that of the control group at the respective visits.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, single center study. Data will be collected at baseline, time of procedure (trial and permanent), trial phase, and at 1, 3, 6, 12 and 15 months post-implantation.
The primary objective of this study is to collect data on Neuromodulation to Augment Pain and Rehabilitation in Spinal Cord Injury (SCI), a real-world population while further characterizing neurophysiological measures and clinical outcomes.
The following data will be collected:
- Baseline characteristics and demographics
- Procedure characteristics
- Medications
- 10-point Numerical Rating Scales (NRS) for pain intensity Guy/Farrar Patient Global Impression of Change (PGIC) scale ASIA motor and sensory scores and impairment grade
- QoL survey (PROMIS 29)
- Electromyography (EMG) / Nerve Conduction Studies (NCS)
- Spinal Cord Independence Measure (SCIM) survey
- Ashworth spasticity scale
- Bladder control using standard clinical urodynamic studies
- Programming parameters and characteristics
- Safety events (adverse events, device deficiencies, protocol deviations)
The outcome variables of interest will be collected and assessed across study visits. No pre-planned formal statistical hypothesis tests will be performed. Multivariable regression modeling and descriptive statistics will be utilized.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Beth Perry, RN
- Phone Number: 919-681-2695
- Email: beth.perry@duke.edu
Study Contact Backup
- Name: Allison Spell
- Phone Number: 919-681-4937
- Email: allison.spell@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Health Systems
-
Contact:
- Allison Spell
- Phone Number: 919-681-4937
- Email: allison.spell@duke.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects enrolled in this study must meet all of the following inclusion criteria (based on investigator judgement):
- Traumatic, thoracic SCI
- Chronic pain (i.e., Pain >3 for > 3 months)
- Willing and able to provide informed consent, attend required study visits, and complete required assessments/questionnaires
- 18-80 years of age
- Medically stable enough to undergo surgical implantation of an SCS / participate in rehabilitation regimens
Exclusion Criteria:
Subjects enrolled in this study must not meet any of the following exclusion criteria (based on investigator judgement):
- Complete cord transection
- Persistent spinal instability or other injury preventing ability to participate
- Active infection
- Comorbid psychosis or psychotic disorder
- Untreated, clinically significant depression
- Active drug or alcohol abuse
- Pregnant women or women who intend to become pregnant during the duration of the study. Women of childbearing potential need a negative pregnancy test
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EES on
Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES on.
Both the patient and the provider will be formally blinded to treatment assignment.
Only the biostatistician and programming team will be unblinded to treatment assignments.
|
Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
Other Names:
|
Placebo Comparator: EES off
Patients will undergo epidural electrical stimulation (EES) and be randomized in a 1:1 allocation to EES off.
Both the patient and the provider will be formally blinded to treatment assignment.
Only the biostatistician and programming team will be unblinded to treatment assignments.ES off.
Those in the EES off category will have their EES turned on at the 9-month timepoint.
|
Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Multidimensional Pain Inventory (MPI)-SCI average activity score
Time Frame: Baseline, 9 months
|
The MPI-SCI consists of twelve 7-point subscales in three sections: (1) pain impact, (2) responses by significant others, and (3) activity.
Our primary outcome is the average score of the 4 pain subscales (household activities, activities away from home, social activities, and outdoor work) for pain and consequences of SCI.
These 4 scales are commonly used to create a single general activity scale.
To define the degree to which pain and other consequences of injury reduced participation in a specific activity, 2 additional validated items will be used in section 3: (1) "Pain has reduced my participation in this activity," and (2) "Other consequences of SCI have reduced my participation in this activity."
The response range from 0 (not at all) to 6 (extremely).
|
Baseline, 9 months
|
Motor recovery as measured by EMG
Time Frame: Up to 9 months
|
EMGs will be recorded using surface or needle electrodes placed over/in the following muscles: bilateral gluteus maximus, bilateral rectus femoris, bilateral vastus lateralis, bilateral medial hamstrings, bilateral anterior tibialis and bilateral gastrocnemius.
When clinically appropriate, bilateral extensor carpi radialis, bilateral biceps, and bilateral abdominal muscles will be used as controls.
|
Up to 9 months
|
Motor recovery as measured by dynamometry
Time Frame: Up to 9 months
|
Dynamometry will be used to measure muscle force by the same blinded rater for each of the muscle groups as an additional measure of muscle contraction activity.
|
Up to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain as measured by 10-point Numeric Rating Scales (NRS)
Time Frame: Baseline, 9 months
|
Validated assessment of pain severity (0-10 scale), 0 being no pain to 10 being the worst pain, in the past 7 days.
|
Baseline, 9 months
|
Change in Quality of Life (QOL) as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) 29
Time Frame: Baseline, 9 months
|
The PROMIS-29 is a generic health-related quality of life survey that assesses each of the 7 PROMIS domains with 4 questions.
The questions are ranked on a 5-point Likert Scale.
PROMIS instruments contain a fixed number of items from seven PROMIS domains: depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; and ability to participate in social roles and activities.
The seven domains cover the most relevant areas of self-reported health for the greatest majority of people with chronic illness.
|
Baseline, 9 months
|
Change in the number of prescriptions written as measured by Electronic Health Record abstraction.
Time Frame: Baseline, 9 months
|
Baseline, 9 months
|
|
Change in the number of opioid prescriptions filled as measured by Electronic Health Record abstraction.
Time Frame: Baseline, 9 months
|
Baseline, 9 months
|
|
Change in the overall improvement as measured by Guy/Farrar Patient Global Impression of Change (PGIC) scale
Time Frame: Baseline, 9 months
|
The self-report measure PGIC reflects a patient's belief about the efficacy of treatment.
PGIC is a 7 point scale depicting a patient's rating of overall improvement.
|
Baseline, 9 months
|
Change in motor recovery as measured by the Total American Spinal Injury Association (ASIA) motor score
Time Frame: Baseline, 9 months
|
ASIA Upper Extremity and Lower Extremity Motor Score (UEMS & LEMS), combine to give Total ASIA Motor Score.
|
Baseline, 9 months
|
Change in motor recovery as measured by the ASIA impairment grades
Time Frame: Baseline, 9 months
|
The ASIA Impairment Scale (AIS), based on the Frankel scale, is a clinician-administered scale used to classify the severity (completeness) of injury in individuals with SCI.
It identifies sensory and motor levels indicative of the highest spinal level demonstrating "unimpaired" function.
Preservation of function in the sacral segments (S4-S5) is a key for determining the AIS grade.
AIS scores are considered essential when classifying persons with SCI as to their neurological status.
|
Baseline, 9 months
|
Change in independence of activities of daily living (ADLs) as measured by the Spinal Cord Independence Measure (SCIM) survey
Time Frame: Baseline, 9 months
|
SCIM Disability scale developed to specifically address the ability of SCI patients to perform basic activities of daily living independently.
Three versions of the SCIM (I-III) have been consecutively developed and assess three areas: 1) self-care (feeding, grooming, bathing, and dressing); 2) respiration and sphincter management; 3) mobility (bed and transfers and indoor/outdoor).
The item scores are weighted related to the assumed clinical relevance.
|
Baseline, 9 months
|
Change in limb movement as measured by the Ashworth spasticity scale
Time Frame: Baseline, 9 months
|
The Ashworth scale is the most widely used assessment tool to measure resistance to limb movement in a clinic setting, although it is unable to distinguish between the neural and non-neural components of increased tone.
|
Baseline, 9 months
|
Change in bladder control using urodynamics
Time Frame: Baseline, 9 months
|
A urodynamic test is used to measure nerve and muscle function, pressure around and in the bladder, flow rates, and other factors.
These tests look at how well the bladder, sphincters, and urethra are storing and releasing urine.
All measures are combined to give one overall score of bladder control.
|
Baseline, 9 months
|
Change in motor recovery as measured by Transcranial Magnetic Stimulation Motor Evoked Potentials (TMS MEPs)
Time Frame: Baseline, 9 months
|
To evaluate the connectivity of descending motor signals passing through the injury, TMS MEPs are recorded bilaterally over the rectus femoris (RF), vastus lateralis (VL), medial hamstring (MH), tibialis anterior (TA), medial gastrocnemius (MG), and soleus (SOL) muscles using skin surface EMG at a sampling rate of 4 kHz.
|
Baseline, 9 months
|
Change in sensory recovery as measured by Somatosensory Evoked Potentials (SSEPs)
Time Frame: Baseline, 9 months
|
SSEPs will be recorded over the scalp and lumbar spine region to detect ascending sensory signals across the injury.
To test for the presence of a dis-complete SCI profile, the subject was positioned supine, and while EES was off, he attempted to maximally contract muscles both above and below the injury with intention focused on increasing motor activity in either the left or right leg.
|
Baseline, 9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shivanand Lad, MD, PhD, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00106738
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury at T1-T12 Level
-
Kevin KilgoreNational Institute of Neurological Disorders and Stroke (NINDS); Case Western... and other collaboratorsRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury Cervical | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
S.Biomedics Co., Ltd.Yonsei University; Linical Co., Ltd.RecruitingSpinal Cord Injury, Acute | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C4 Level With Complete LesionKorea, Republic of
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
-
Azienda Ospedaliero, Universitaria PisanaCompletedSpinal Cord Injury at C5-C7 Level
-
Nicholls Spinal Injury FoundationUniversity College, London; Poznan University of Medical Sciences; Wroclaw Medical... and other collaboratorsRecruitingSpinal Cord Injury at C5-Th10 Level With Complete Lesion | Spinal Cord TransectionPoland
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonNo longer availableSpinal Cord Injury at C5-C7 LevelUnited States
-
Ohio State UniversityCompletedSpinal Cord Injury at C4-C6 LevelUnited States
-
Bronx VA Medical CenterNew York State Department of HealthCompletedSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Tetraplegia/TetraparesisUnited States
-
University of ManitobaRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Paraplegia, Spinal | Paraplegia, IncompleteCanada
-
University of British ColumbiaUniversity of Toronto; Queen's University; Dalhousie University; Wings for LifeRecruitingUpper Extremity Dysfunction | Cervical Spinal Cord Injury | Spinal Cord Injury | Spinal Cord Injury at C5-C7 Level | SCI - Spinal Cord Injury | Upper Extremity Paralysis | Tetraplegia | Upper Extremity ParesisCanada
Clinical Trials on EES on
-
Buddhist Tzu Chi General HospitalRecruiting
-
Hospital Universitari de BellvitgeUnknown
-
Sang Sik ChoiSewoon Medical Co., LtdUnknownEpidural AnalgesiaKorea, Republic of
-
Lee Fisher, PhDEnrolling by invitationCardiovascular Diseases | Stroke | Brain Diseases | Central Nervous System Diseases | Nervous System DiseasesUnited States
-
Hyogo Brain and Heart CenterUnknownSTEMI | ST-elevation Acute Myocardial InfarctionJapan
-
Deutsches Herzzentrum MuenchenUnknownTest Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)Coronary StenosisGermany
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedChild Development | Child Behavior Disorders | Reactive Attachment DisorderUnited States
-
ECRI bvMicell Technologies; StentysCompletedCoronary StenosisFrance, Germany, Netherlands, Poland
-
Yonsei UniversityCompletedIschemic Heart DiseaseKorea, Republic of
-
A.O. Ospedale Papa Giovanni XXIIIUnknown